ALX Oncology (NasdaqGS:ALXO) FY Conference Transcript

Summary of ALX Oncology FY Conference Call (March 03, 2026) Company Overview - Company: ALX Oncology (NasdaqGS:ALXO) - Key Personnel: Jason Lettmann (CEO), Dr. Barbara Klencke (Chief Medical Officer) - Focus: Advancing two novel oncology treatments: evorpacept (EVO) and ALX2004 [2][3] Core Programs Evorpacept (EVO) - Type: Novel CD47-targeting therapy - Development: In development since 2015, focusing on how cancer evades immune detection via CD47 [2][3] - Clinical Focus: - Currently targeting breast cancer, particularly post-HER2 treatment patients [4][5] - ASPEN breast study aims to enroll 80 patients, with top-line data expected in mid-2027 [4][20] - Clinical Data: - ASPEN-06 study showed a 65% response rate in HER2-positive patients compared to 26% in the control arm, indicating a 40% delta [10][11] - Combination studies with other therapies (e.g., Herceptin, zanidatamab) have shown promising results [6][10] - Safety Profile: No significant on-target toxicities reported, differentiating from conventional CD47 therapies [8][17] ALX2004 - Type: EGFR-targeted antibody-drug conjugate (ADC) - Development: Focused on minimizing skin toxicity and maximizing therapeutic window [21][22] - Clinical Trials: - Ongoing dose escalation studies, with safety data expected in the second half of 2026 [27] - Targeting EGFR overexpressing tumors, including lung, head and neck, colorectal, and esophageal cancers [27] - Unique Features: - Utilizes a proprietary linker and TOPO1 payload, aiming for improved efficacy and safety [22][23] Financials - Recent Financing: Closed a financing round of $150 million, funding operations through the first half of 2028 [5][30] - Market Opportunity: Approximately 20,000 addressable patients in the HER2-positive and CD47 overexpressing population [20] Strategic Outlook - Execution Focus: Emphasis on executing clinical studies and achieving pivotal readiness for both programs by the end of 2027 [28][30] - Partnership Opportunities: Open to collaborations, with a successful history of partnerships (e.g., with Sanofi) [32][33] - Market Positioning: Positioned to address significant unmet needs in oncology, particularly in breast cancer and EGFR-related tumors [28][29] Additional Insights - Clinical Validation: The unique mechanism of action of EVO, using a dead Fc to avoid on-target toxicity, has been validated across multiple studies [6][8] - Response Rates: High response rates in various cancer settings indicate the potential of both EVO and ALX2004 to change treatment paradigms [10][12][13] - Future Data: Upcoming data presentations at major conferences (e.g., ESMO Breast Cancer 2026) are anticipated to further validate the efficacy of these treatments [19][20]